1
|
Systematic review of genetic variants associated with cognitive impairment and depressive symptoms in Parkinson's disease. Acta Neuropsychiatr 2020; 32:10-22. [PMID: 31292011 DOI: 10.1017/neu.2019.28] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
OBJECTIVE Cognitive impairment and depression are among the most prevalent and most disabling non-motor symptoms in Parkinson's disease (PD). The genetic factors that are associated with these symptoms remain uncertain. This systematic review aims to summarise the prevailing evidence from all genetic association studies investigating the genetic variants associated with cognitive impairment and depressive symptoms in people with PD. METHOD A systematic review using five online databases: PubMed, PsycINFO, CINAHL, EMBASE and OpenGrey (PROSPERO protocol: CRD42017067431). We completed the quality assessment using the Q-Genie tool. RESULTS 2353 articles were screened, and 43 articles were found to be eligible to be included. A meta-analysis of studies investigating LRRK2 rs34637584 confirmed that the minor allele carriers had significantly less cognitive impairment (p = 0.015). Further meta-analyses showed that GBA variants rs76763715 (p < 0.001) and rs421016 (p = 0.001) were significantly associated with more cognitive impairment in people with PD. Minor alleles of GBA variants rs76763715, rs421016, rs387906315 and rs80356773 were associated with more depressive symptoms in PD. Moreover, APOE ε4 allele has been associated with more cognitive impairment in PD. BDNF (rs6265) and CRY1 (rs2287161) variants have been associated with more depressive symptoms in people with PD. CONCLUSIONS PD carriers of GBA variants are at high risk for cognitive decline and depression. Screening for these variants may facilitate early identification and effective management of these non-motor symptoms. The molecular mechanisms underlying favourable cognitive functioning in LRRK2 rs34637584 variant carriers warrant further investigation.
Collapse
|
2
|
Abstract
The human dopamine transporter gene SLC6A3 is involved in substance use disorders (SUDs) among many other common neuropsychiatric illnesses but allelic association results including those with its classic genetic markers 3'VNTR or Int8VNTR remain mixed and unexplainable. To better understand the genetics for reproducible association signals, we report the presence of recombination hotspots based on sequencing of the entire 5' promoter regions in two small SUDs cohorts, 30 African Americans (AAs) and 30 European Americans (EAs). Recombination rate was the highest near the transcription start site (TSS) in both cohorts. In addition, each cohort carried 57 different promoter haplotypes out of 60 and no haplotypes were shared between the two ethnicities. A quarter of the haplotypes evolved in an ethnicity-specific manner. Finally, analysis of five hundred subjects of European ancestry, from the 1000 Genome Project, confirmed the promoter recombination hotspots and also revealed several additional ones in non-coding regions only. These findings provide an explanation for the mixed results as well as guidance for selection of effective markers to be used in next generation association validation (NGAV), facilitating the delineation of pathogenic variation in this critical neuropsychiatric gene.
Collapse
|
3
|
Genetic risk factors and gene–environment interactions in adult and childhood attention-deficit/hyperactivity disorder. Psychiatr Genet 2019; 29:63-78. [DOI: 10.1097/ypg.0000000000000220] [Citation(s) in RCA: 40] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
|
4
|
Kanno K, Ishiura S. Differential effects of the HESR/HEY transcription factor family on dopamine transporter reporter gene expression via variable number of tandem repeats. J Neurosci Res 2011; 89:562-75. [DOI: 10.1002/jnr.22593] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2010] [Revised: 11/10/2010] [Accepted: 12/09/2010] [Indexed: 11/08/2022]
|
5
|
Amiri S, Fakhari A, Maheri M, Mohammadpoor Asl A. Attention deficit/hyperactivity disorder in primary school children of Tabriz, North-West Iran. Paediatr Perinat Epidemiol 2010; 24:597-601. [PMID: 20955237 DOI: 10.1111/j.1365-3016.2010.01145.x] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
This study aimed to estimate the prevalence of attention deficit/hyperactivity disorder (ADHD), as well as its subtypes, in elementary school children and their demographic characteristics. A random clustered sample of elementary students was selected from schools of Tabriz, North-West Iran. The clinical diagnosis of ADHD was based on DSM-IV-TR criteria using an interview with children who were selected as scoring high on the Conner's teacher rating scale. A total of 30 schools and 1658 students were evaluated. The prevalence rate of clinical ADHD in the elementary students of Tabriz was 9.7%. Only two had been diagnosed previously. The mean age (standard deviation) was 9.39 (1.27) years. ADHD was more common among boys, students of the third level and children with an un-educated mother or father. It was not related to the type of school, age or birth order. Students with ADHD had lower school performance and orderliness reported by the school. Inattentiveness was more common among schoolgirls while the most common subtype was the combined one. Inattentive students had a significantly lower school performance. ADHD is common in elementary schools of this region and is correlated with poor performance. Greater awareness of parents and teachers concerning children at risk is necessary for an early diagnosis.
Collapse
Affiliation(s)
- Shahrokh Amiri
- Department of Psychiatry, Tabriz University of Medical Sciences, Tabriz, Iran.
| | | | | | | |
Collapse
|
6
|
Yeh YW, Lu RB, Tao PL, Shih MC, Lin WW, Huang SY. Neither single-marker nor haplotype analyses support an association between the dopamine transporter gene and heroin dependence in Han Chinese. GENES BRAIN AND BEHAVIOR 2010; 9:638-47. [PMID: 20497233 DOI: 10.1111/j.1601-183x.2010.00597.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Much evidence suggests that dysfunction of dopamine transporter-mediated dopamine transmission may be involved in the pathophysiology of substance abuse and dependence. The aim of this study was to examine whether the dopamine transporter gene (DAT1; SLC6A3) is associated with the development of heroin dependence (HD) and whether DAT1 influences personality traits in patients with HD. Polymorphisms of DAT1 were analyzed in a case-control study of 1046 Han Chinese (615 patients and 431 controls). All participants were screened using a Chinese version of the modified Schedule of Affective Disorder and Schizophrenia-Lifetime and all patients met the criteria for HD. Furthermore, a Chinese version of the Tridimensional Personality Questionnaire (TPQ) was used to assess personality traits in the patient group and examine the association between their personality traits and DAT1 polymorphisms. Of the patient group, 271 completed the TPQ. No statistically significant differences in allele or genotype frequencies of all investigated variants between HD patients and controls were observed. In haplotype analyses, four haplotype blocks of DAT1 were not associated with the development of HD. These DAT1 polymorphisms did not influence novelty seeking and harm avoidance scores in HD patients. This study suggests that the DAT1 gene may not contribute to the risk of HD and specific personality traits in HD among the Han Chinese population.
Collapse
Affiliation(s)
- Y-W Yeh
- Department of Psychiatry, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan
| | | | | | | | | | | |
Collapse
|
7
|
Warton FL, Howells FM, Russell VA. Increased glutamate-stimulated release of dopamine in substantia nigra of a rat model for attention-deficit/hyperactivity disorder--lack of effect of methylphenidate. Metab Brain Dis 2009; 24:599-613. [PMID: 19821016 DOI: 10.1007/s11011-009-9166-1] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/15/2009] [Accepted: 07/18/2009] [Indexed: 02/06/2023]
Abstract
Attention-deficit/hyperactivity disorder (ADHD) is a behavioural disorder that has been associated with dysfunction of the dopaminergic system. Abnormal dopamine function could be the result of a primary defect in dopamine neurons (neuronal firing, dopamine transporter, synthesis, receptor function) or an indirect result of impaired glutamate and/or noradrenergic regulation of dopamine neurons. There is considerable evidence to suggest that dopamine release is impaired at mesolimbic and nigrostriatal dopaminergic terminals. However, it is not known whether dysregulation occurs at the level of the cell bodies in the ventral tegmental area of the midbrain (VTA) and substantia nigra (SN). An in vitro superfusion technique was used to measure dopamine release in a widely used model of ADHD, the spontaneously hypertensive rat (SHR), and its normotensive Wistar-Kyoto (WKY) control. At approximately 30 days of age, rats were analysed for behavioural differences in the open field in response to acute treatment with methylphenidate (0.5 to 2 mg/kg in condensed milk, oral self-administration). In addition, rats were treated chronically with methylphenidate (2 mg/kg, oral self-administration, twice daily for 14 days from postnatal day 21 to 34) before the VTA and the SN were analysed for glutamate-stimulated and depolarization-evoked release of dopamine in these areas. In support of its use as an animal model for ADHD, SHR were more active in the open field and displayed less anxiety-like behaviour than WKY. Neither strain showed any effect of treatment with methylphenidate. A significant difference was observed in glutamate-stimulated release of dopamine in the SN of SHR and WKY, with SHR releasing more dopamine, consistent with the hypothesis of altered glutamate regulation of dopamine neurons in SHR.
Collapse
Affiliation(s)
- Fleur L Warton
- Division of Physiology, Department of Human Biology, University of Cape Town, Observatory, Cape Town, 7925, South Africa
| | | | | |
Collapse
|
8
|
Shibuya N, Kamata M, Suzuki A, Matsumoto Y, Goto K, Otani K. The −67 A/T promoter polymorphism in the dopamine transporter gene affects personality traits of Japanese healthy females. Behav Brain Res 2009; 203:23-6. [DOI: 10.1016/j.bbr.2009.04.008] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2009] [Revised: 04/07/2009] [Accepted: 04/09/2009] [Indexed: 10/20/2022]
|
9
|
Doyle C, Brookes K, Simpson J, Park J, Scott S, Coghill DR, Hawi Z, Kirley A, Gill M, Kent L. Replication of an association of a promoter polymorphism of the dopamine transporter gene and Attention Deficit Hyperactivity Disorder. Neurosci Lett 2009; 462:179-81. [PMID: 19576958 DOI: 10.1016/j.neulet.2009.06.084] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2009] [Revised: 06/18/2009] [Accepted: 06/27/2009] [Indexed: 01/07/2023]
Abstract
Genetic associations for Attention Deficit Hyperactivity Disorder (ADHD), a common highly heritable childhood behavioural disorder, require replication in order to establish whether they are true positive findings. The current study aims to replicate recent association findings from the International Multi-centre ADHD Genetics (IMAGE) project in one of the most studied genes related to ADHD, the dopamine transporter (DAT1) gene. In a family-based sample of 450 ADHD probands, three Single Nucleotide Polymorphism (SNP) markers have been genotyped using TaqMan assays. Transmission Disequilibrium Test analysis demonstrates that one of three SNP markers (rs11564750) in the 5' promoter region of the gene is significantly associated with ADHD (P=0.02). This provides further evidence that in addition to the well-known and investigated 3'UTR polymorphism associated with ADHD, there is potentially a further association signal emanating from the 5' promoter region of the gene. Further replication and functional studies are now required to fully understand the consequence of polymorphisms present at both the 5' and 3' ends of the DAT1 gene and their role in ADHD pathophysiology.
Collapse
Affiliation(s)
- Christopher Doyle
- Bute Medical School, University of St Andrews, Westburn Lane, St Andrews, Scotland KY16 9TS, United Kingdom
| | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Dissanayaka NNW, Silburn PA, O'Sullivan JD, Mellick GD. Serotonin and dopamine transporter genes do not influence depression in Parkinson's disease. Mov Disord 2009; 24:111-5. [PMID: 18973248 DOI: 10.1002/mds.22134] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Altered levels of the neurotransmitters dopamine and serotonin are observed in both Parkinson's disease (PD) and depression. Therefore, the neurotransmitter transporter genes, SLC6A3 (dopamine) and SLC6A4 (serotonin) are candidates for depression in PD. We genotyped 24 tagging SNPs together with VNTRs and the SLC6A4 LPR polymorphism in 190 PD patients categorised according to lifetime history of depression. Log-additive, dominant and recessive statistical models were constructed. No significant genotype or haplotype associations were observed suggesting that common genetic variables around the dopamine and serotonin transporter genes do not play a significant role in the etiology of depression in PD.
Collapse
|
11
|
Stam AJ, Schothorst PF, Vorstman JA, Staal WG. The genetic overlap of attention deficit hyperactivity disorder and autistic spectrum disorder. APPLICATION OF CLINICAL GENETICS 2009; 2:7-13. [PMID: 23776346 PMCID: PMC3681037 DOI: 10.2147/tacg.s4683] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
Autistic spectrum disorders (ASD) and attention deficit hyperactivity disorder (ADHD) are classified as distinct disorders within the DSM-IV-TR (1994). The manual excludes simultaneous use of both diagnoses in case of overlap on a symptomatic level. However this does not always represent clinical observations and findings of previous studies. This review explores the genetic basis of the phenomenological overlap between ADHD and ASD. Based on an extensive review of twin-, linkage-, association studies, and reported structural genomic abnormalities associated with these disorders, we have identified seventeen regions on the human genome that can be related to both disorders. These regions of shared genetic association are: 2q35, 3p14, 4p16.1, 4p16.3, 5p15.31, 5p15.33, 7p12.3, 7p22, 7q21, 8q24.3, 14q12, 15q11–12, 16p13, 17q11, 18q21–23, 22q11.2, Xp22.3. The presented data are of interest for future genetic studies and appear to suggest the existence of a phenotype partition that may differ from the current classification of psychiatric disorders.
Collapse
Affiliation(s)
- Arie J Stam
- University Medical Center Utrecht (UMC Utrecht), Utrecht, The Netherlands
| | | | | | | |
Collapse
|
12
|
Xu X, Mill J, Sun B, Chen CK, Huang YS, Wu YY, Asherson P. Association study of promoter polymorphisms at the dopamine transporter gene in Attention Deficit Hyperactivity Disorder. BMC Psychiatry 2009; 9:3. [PMID: 19196467 PMCID: PMC2644291 DOI: 10.1186/1471-244x-9-3] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/25/2008] [Accepted: 02/05/2009] [Indexed: 12/21/2022] Open
Abstract
BACKGROUND Attention deficit hyperactivity disorder (ADHD) is a complex neurobehavioral disorder. The dopamine transporter gene (DAT1/SLC6A3) has been considered a good candidate for ADHD. Most association studies with ADHD have investigated the 40-base-pair variable number of tandem repeat (VNTR) polymorphism in the 3'-untranslated region of DAT1. Only few studies have reported association between promoter polymorphisms of the gene and ADHD. METHODS To investigate the association between the polymorphisms -67A/T (rs2975226) and -839C/T (rs2652511) in promoter region of DAT1 in ADHD, two samples of ADHD patients from the UK (n = 197) and Taiwan (n = 212) were genotyped, and analysed using within-family transmission disequilibrium test (TDT). RESULTS A significant association was found between the T allele of promoter polymorphism -67A/T and ADHD in the Taiwanese population (P = 0.001). There was also evidence of preferential transmission of the T allele of -67A/T polymorphism in combined samples from the UK and Taiwan (P = 0.003). No association was detected between the -839C/T polymorphism and ADHD in either of the two populations. CONCLUSION The finding suggests that genetic variation in the promoter region of DAT1 may be a risk factor in the development of ADHD.
Collapse
Affiliation(s)
- Xiaohui Xu
- MRC Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, King's College London, UK.
| | - Jonathan Mill
- MRC Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, King's College London, UK
| | - Bo Sun
- School of Medicine, King's College London, UK
| | - Chih-Ken Chen
- Department of Psychiatry, Chang Gung Memorial Hospital, Taiwan,Chang Gung University School of Medicine, Taiwan
| | - Yu-Shu Huang
- Chang Gung University School of Medicine, Taiwan,Department of Child Psychiatry, Chang Gung Children's Hospital, Taiwan
| | - Yu-Yu Wu
- Chang Gung University School of Medicine, Taiwan,Department of Child Psychiatry, Chang Gung Children's Hospital, Taiwan
| | - Philip Asherson
- MRC Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, King's College London, UK
| |
Collapse
|
13
|
Brookes KJ, Xu X, Anney R, Franke B, Zhou K, Chen W, Banaschewski T, Buitelaar J, Ebstein R, Eisenberg J, Gill M, Miranda A, Oades RD, Roeyers H, Rothenberger A, Sergeant J, Sonuga-Barke E, Steinhausen HC, Taylor E, Faraone SV, Asherson P. Association of ADHD with genetic variants in the 5'-region of the dopamine transporter gene: evidence for allelic heterogeneity. Am J Med Genet B Neuropsychiatr Genet 2008; 147B:1519-23. [PMID: 18668530 DOI: 10.1002/ajmg.b.30782] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
Multiple studies have reported an association between attention deficit hyperactivity disorder (ADHD) and the 10-repeat allele of a variable number tandem repeat (VNTR) polymorphism in the 3'-untranslated region (3'UTR) of the dopamine transporter gene (DAT1). Yet, recent meta-analyses of available data find little or no evidence for this association; although there is strong evidence for heterogeneity between datasets. This pattern of findings could arise for several reasons including the presence of relatively rare risk alleles on common haplotype backgrounds or the functional interaction of two or more loci within the gene. We previously described the importance of a specific haplotype at the 3' end of DAT1, as well as the identification of associated single nucleotide polymorphisms (SNPs) within or close to 5' regulatory sequences. In this study we replicate the association of SNPs at the 5' end of the gene and identify a specific risk haplotype spanning the 5' and 3' markers. These findings indicate the presence of at least two loci associated with ADHD within the DAT1 gene and suggest that either additive or interaction effects of these two loci on the risk for ADHD. Overall these data provide further evidence that genetic variants of the dopamine transporter gene confer an increased risk for ADHD.
Collapse
Affiliation(s)
- K J Brookes
- MRC Social Genetic Developmental and Psychiatry Centre, Institute of Psychiatry, London, UK
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Abstract
The search for genes influencing the development of attention-deficit/hyperactivity disorder (ADHD) has identified a number of associated genes within, or influencing, the dopamine neurotransmitter system. The focus on this system as the site of genetic susceptibility was prompted by information from animal models, particularly transgenics, as well as the mechanism of action of the psychostimulants, the primary pharmacological treatment for ADHD. Thus far, genes in the dopamine system reported as associated with ADHD, by at least one study, include the dopamine transporter, the dopamine receptors D1, D4 and D5, as well as genes encoding proteins that control the synthesis, degradation and release of dopamine. For some of these genes, replication across studies provides evidence supporting the relationship; however, for others, the data is far from conclusive and further work is needed. The quick progress in the genetic findings was initially surprising given the complexity of the phenotype and the relatively small sample sizes used in the initial studies. However, the high heritability of ADHD, as indicated by twin studies, may have contributed to the success. The genes studied so far are estimated to contribute only weakly or moderately to the risk for the development of ADHD. This may be because these genes, in fact, make only a small contribution. However, few studies have comprehensively examined the genetic information across the gene. This will lead to underestimates of risk if the polymorphism(s) tested is/are not the functional change(s) actually contributing to the genetic susceptibility and if linkage disequilibrium between tested marker(s) and causal variant(s) is weak, or if there is substantial allelic heterogeneity. While the studies thus far are very promising, virtually nothing is known on precisely how genetic variation in these genes actually contributes to risk; thus, functional studies are now required.
Collapse
Affiliation(s)
- Cathy L Barr
- Room MP14-302, Genetics & Development Division, The Toronto Western Hospital, 399 Bathurst St, Toronto, ON, Canada M5T 2S8
| | - Virginia L Misener
- Genetics and Development Division, Toronto Western Research Institute, University Health Network, Toronto, ON, Canada
| |
Collapse
|
15
|
Zhang A, Xing Q, Wang L, Du J, Yu L, Lin Z, Li X, Feng G, He L. Dopamine transporter polymorphisms and risperidone response in Chinese schizophrenia patients: an association study. Pharmacogenomics 2008; 8:1337-45. [PMID: 17979508 DOI: 10.2217/14622416.8.10.1337] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Risperidone is a widely used atypical antipsychotic medication and there is currently considerable interest in individual differences in patient response to it. In this study, we investigated the pharmacogenetic correlates of SLC6A3 and response to risperidone treatment in 130 Chinese schizophrenia patients. We selected six polymorphisms, including two SNPs in the 5'-regulatory regions, two SNPs in intron 1, one SNP and a variable number tandem repeat in the 3'-flanking region of SLC6A3 for this study and analyzed the differences in the reduction of Positive and Negative Syndrome Scale (PANSS) scores among the subgroups with different genotypes and diplotypes after 8 weeks of risperidone treatment. The confounding effects of nongenetic factors were estimated and the baseline symptom score was included as a covariate for adjustment. We found no significant differences in response to treatment in terms of PANSS or subscores improvements among the subgroups according to different genotypes and diplotypes. In addition, we have found no significant differences between different diplotypic groups in the plasma levels of risperidone and 9-hydroxyrisperidone. Further studies on larger groups and on the effects of longer-term risperidone treatment are needed to confirm these results.
Collapse
Affiliation(s)
- Aiping Zhang
- Shanghai Jiao Tong University, Bio-X Center, Haoran Building, 1954 Huashan Road, Shanghai 200030, China
| | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Banoei MM, Majidizadeh T, Shirazi E, Moghimi N, Ghadiri M, Najmabadi H, Ohadi M. No association between the DAT1 10-repeat allele and ADHD in the Iranian population. Am J Med Genet B Neuropsychiatr Genet 2008; 147B:110-1. [PMID: 17582621 DOI: 10.1002/ajmg.b.30578] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
Association studies between attention-deficit hyperactivity disorder (ADHD) and the 10-repeat allele of a polymorphism (a 40 bp variable number of tandem repeats) in the dopamine transporter gene (DAT1) have resulted in mixed findings in different populations. We performed a case/control study to clarify the contribution of this allele with ADHD in the Iranian population. No association was observed between the 10-allele and disease (chi(2) = 0.081, P < 0.9). Furthermore, no significant difference was observed in the homozygosity of this allele between the case and control groups (chi(2) = 0.022, P < 0.9). Implication of the dopamine transporter gene in the pathophysiology of ADHD warrants investigation of other functional polymorphisms within this gene in the Iranian ADHD patients.
Collapse
Affiliation(s)
- M M Banoei
- National Institute for Genetic Engineering and Biotechnology, Tehran, Iran
| | | | | | | | | | | | | |
Collapse
|